Introduction
Sputum-scarce and smear-negative tuberculosis (TB) continues to pose a diagnostic conundrum to clinicians because the yield of rapid diagnostic tools is low and obtaining representative biological samples may be challenging. Smear microscopy has a poor sensitivity and culture results take several weeks to obtain. Empiric treatment exposes patients to prolonged treatment with toxic drugs, and if this fails, possible unnecessary therapy for drugresistant TB. The only alternative rapid diagnostic tool, nucleic acid amplification testing (NAAT), has a variable and sub-optimal sensitivity (~40 % in smear negative pulmonary TB [1] .
Pulmonary TB is characterized by a robust Th1 response raising the prospect of rapid immunodiagnosis using TB antigen-driven alveolar T-cell IFN-γ responses [2] [3] [4] [5] [6] [7] . Alveolar PPD-specific T cell responses have been investigated as a TB diagnostic tool [8] . However, PPD may drive pulmonary memory T cell responses in those with latent TB infection [6] and/ or exposure to non-tuberculous mycobacteria, and thus may have limited specificity. More recently, standardized rapid immunodiagnostic assays (T-SPOT.
® TB and QuantiFERON
® -TB Gold-In-Tube), which evaluate IFN-γ responses to the RD-1 antigens ESAT-6 and CFP-10 have been shown to be highly sensitive and specific tests for the diagnosis of TB infection [9] [10] [11] but they cannot distinguish latent from active disease when using peripheral blood mononuclear cells [12] . However, at the site of active tuberculosis, in contrast to non tuberculous disease, there is a ~10 fold higher frequency of TB antigen-specific T cells [13] [14] [15] . Thus, it is reasonable to hypothesize that lung-orientated rapid immunodiagnosis of TB is possible using cells from affected pulmonary segments. Indeed, a preliminary study performed in Europe indicated that TB could be rapidly and accurately diagnosed with the T-SPOT.
® TB assay using broncho-alveolar lavage mononuclear cells (BALMCs; [16] ). However, it remains unclear whether these outcomes can be reproduced in routine clinical practice, particularly, in a high burden TB and HIV setting where it would be most useful.
There are also several other unresolved questions. It is unclear whether alveolar antigenspecific responses distinguish between active and LTBI, how HIV infection impacts upon pulmonary immune responses, and which antigens are most useful. The comparative diagnostic utility of the different standardized RD-1 assays (QuantiFERON ® -TB Gold-In-Tube and T-SPOT.
® TB) and other novel antigens (heparin-binding-haemagglutinin (HBHA)) have not previously been evaluated using BALMCs. HBHA, a novel and relatively TB-specific antigen, may distinguish latent from active disease [17, 18] and may therefore be particularly well suited to pulmonary immuno-diagnosis. However, in general, data about the immunological profile of TB antigen-specific pulmonary T cells is limited [8, 15, 16] , and the optimal cell number and cut-point needed for reliable immuno-diagnosis is unclear.
To address these questions we prospectively evaluated antigen-specific IFN-γ responses, including a head-to-head comparison between the T-SPOT. ® TB (RD1 ELISPOT) and QuantiFERON ® TB-Gold-In-Tube (RD-1 ELISA; QFT-TB-GIT) assays, and HBHA and PPD responses, using whole blood and BALMCs, in a well categorized cohort of 91 pulmonary TB suspects from Cape Town, South Africa.
Methods

Patient recruitment and investigation
Ninety one consecutive patients with suspected pulmonary tuberculosis who were unable to expectorate sputum (sputum-scarce) or smear-negative were prospectively recruited at Groote Schuur Hospital in Cape Town, South Africa (a study plan is outlined in Figure 1 ). The study protocol was approved by the University of Cape Town Ethics Committee. Six patients were excluded ( Figure 1 ). There were thus 85 patients from whom evaluable samples were obtained. All patients had a history taken, detailed physical examination performed, routine investigations including testing for HIV infection, chest x-ray, and bronchoscopy performed by an experienced pulmonologist under local anaesthesia and conscious sedation. Approximately 150 to 300 ml of sterile saline was used to lavage a radiologically involved lung segment. The aspirate (~100 to 150ml) was collected in a sterile glass bottle. Aliquots of BAL fluid were sent for smear microscopy, Gram and fungal staining, cell differential count, cytology for malignant cells and P. jirovecii, bacterial and fungal culture, and culture for M. tuberculosis (MGIT 960). When appropriate, three to five transbronchial biopsies were performed.
The reference standard for tuberculosis was culture positivity for M. tuberculosis and/ or histology in keeping with tuberculosis (caseous necrosis or acid fast bacilli with or without granuloma formation). Patients were thus characterized by an investigator blinded to the IGRA results as (i) definite TB (meeting the reference standard), (ii) non-TB (alternative diagnosis made and not treated for TB), (iii) probable TB (empiric anti-TB treatment with clinical response but not meeting the reference standard), and (iv) uncertain diagnosis (patient lost to follow-up but not treated for TB and no alternative diagnosis made; thus TB could not be confirmed nor excluded).
Alveolar lymphocyte antigen-specific IFN-γ responses (see online supplement for more detail) The following alveolar antigen-specific IFN-γ responses were evaluated: (i) RD-1 ELISPOT IFN-γ responses to ESAT-6/CFP-10 peptide pools (T-SPOT. ® TB; Oxford Immunotec, England) were performed using 2x10 5 BALMCs per well (cell number selected by performing optimization experiments in 5 patients; see online data supplement for details).
(ii) RD-1 ELISA-measured IFN-γ responses to ESAT-6/ CFP-10 and TB 7.7 antigens (QFT-TB-GIT assay; Cellestis, Victoria) were performed using 1x10 6 BALMCs re-suspended in 1ml of serum free medium in each tube. The cell number and volume used were derived through optimization experiments using BALMCs from 10 patients (see online data supplement). (iii) PPD (10μg/ml; Staten Serum Institute, Denmark) IFN-γ ELISPOT responses were performed in duplicate using IFN-γ pre-coated ELISPOT plates (Mabtech, Sweden) seeded with 2x10 5 BALMCs per well. (iv) IFN-γ ELISPOT responses to HBHA (concentration of 100μg/ml derived from optimization experiments; see online supplement) were performed in duplicate using IFN-γ pre-coated ELISPOT plates. Methylated HBHA antigen was produced in cultures of Mycobacterium smegmatis 3.38 as previously described [19] [20] [21] .
Results were deemed to be inconclusive if there were insufficient cells to perform the assay, if the positive control failed (indeterminate), there was a high spot count/ level in the negative control well/ tube, or, if there was high background discoloration of the ELISPOT wells precluding meaningful evaluation of the plate. In the second half of the study, in addition to phytohaemagglutinin (PHA), staphylococcal enterotoxin B (SEB) was used as a positive control.
Peripheral blood-derived antigen-specific IFN-γ responses Peripheral blood IFN-γ responses (T-SPOT.
® TB, QFT-GIT, PPD and HBHA) were evaluated in each patient according to the methods already described.
Details of the statistical methods used are presented in the online repository. The study satisfies the Standards for Reporting of Diagnostic Accuracy (STARD initiative) checklist [22] .
Results
(i) Demographic and clinical details Demographic characteristics of the recruited patients are shown in Table 1 . Six patients were excluded from further analysis thus there were 85 patients from whom evaluable cellular samples were obtained. Of the 85 patients, 24, 11, 48, and 2 had definite, probable, non-TB and an uncertain diagnosis, respectively. 29% of tested patients (23/78) were HIV positive. Smear microscopy, BAL fluid culture, and transbronchial biopsies (tissue culture and histology) were positive in 7, 23 and 1 of the 24 definite TB cases, respectively, and by definition, in none of the non-TB cases. None of the probable TB cases were culture or biopsy positive but all were treated empirically for TB based on clinical suspicion; all responded to anti-TB treatment. The most common causes of pulmonary infiltrates in the non-TB group are outlined in the online data supplement. The median BAL fluid volume recovered was 100 ml (range = 40 to 200ml). Table 2 (full details are contained in the online supplement; Table E8 ). Inconclusive results were defined as one of the following: (i) failed positive control, (ii) failed negative control (high IFN-γ level or spot count as defined by the manufacturer), (iii) isolation of an inadequate number of cells (as defined in the methods section) to perform the assay, or (iv) high background discoloration of the well precluding result determination (applicable to the ELISPOT assay only).
In 35 ELISPOT assays paired positive controls (PHA and SEB; positive, negative or indeterminate) results were available (PHA and SEB); of these significantly more PHA-driven than SEB-driven positive controls failed [1/28(3%) vs. 7/28(25%); p=0.02; Chi square; Table  E2 online supplement]. In the analysis presented here a failed PHA but functional SEB control was accepted as a valid result. High spot counts in the negative control well, occurred in a higher proportion of HIV positive vs. negative subjects (54% vs. 22% p=0.01), but was not associated with a history of previous TB or BAL bacterial or fungal culture results. The assay-specific (QFT-GIT and T-SPOT. ® TB) sensitivity, specificity, negative and positive predictive values, and area under the ROC of BAL samples are shown in Table 3A (three cutpoints are shown: manufacturer-recommended for peripheral blood and two AUC-derived cutpoints for optimal/ high sensitivity and/ or specificity). In evaluable samples, when the definite and non-tuberculosis groups were used for outcome analysis, the [sensitivity; specificity; positive predictive value; negative predictive value %] for T-SPOT. Table 3B are comparative values when peripheral blood RD-1 responses were evaluated. Outcome values for BAL and blood RD1 responses when the definite and probable TB groups were combined are shown in Table E3 in the online data supplement. Scatter plots and AUC of the ROC of the RD-1 ELISPOT and ELISA BALMC IFN-γ responses are shown Figure 2A and B, respectively. There was moderate agreement between T-SPOT.
® TB and QFT-GIT (76% agreement, κ = 0.47, p=0.001). 0.77 * = manufacturer-recommended cut-point for peripheral blood of > 20 spot forming cells (SFCs) per million mononuclear cells either in the ESAT-6 or CFP-10 containing wells; ** = AUC-derived cut-point with a high specificity at the expense of sensitivity. # = AUC-derived cut-point with the best possible specificity at a high sensitivity; Spec= specificity. n/a = not applicable (this is a dichotomized variable and hence the AUC cannot be calculated.
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RD1 antigen-specific IGRAs using peripheral whole blood T-SPOT. ® Clinical details and laboratory results of non-TB patients with a positive BAL T-SPOT.
® TB or QFT-GIT is shown in Table E4 , whilst clinical details and laboratory results of all definite and probable TB patients with a negative BAL T-SPOT. ® TB or QFT-GIT are shown in Table E5 (online data supplement). In an attempt to improve the discriminatory value of the ELISPOT assay we compared the IFN-γ BALMC/ PBMC ratio in the TB and non-TB groups. We hypothesised that TB patients would have a higher proportion of antigen-specific lymphocytes at the site of disease. Whilst this ratio had a high diagnostic accuracy (AUC = 0.87; 93% sensitivity and 71% specificity at a cut-point of >0.092; Figure E4 , online data supplement) it was no better than the BAL ELISPOT alone. HIV status did not impact on RD-1 ELISPOT or ELISA assay outcomes (see online data supplement; Figure E5 ).
(iii) PPD and HBHA ELISPOT assay Sensitivities and specificity of the BAL and blood PPD and HBHA-driven ELISPOT assay using the definite and non-TB groups, and when definite and probable TB groups were combined, and depending on the cut-point used, is shown in Table E6 and E7 (online data supplement). Outcome values when the definite and probable TB groups were combined are shown in Table E4 (online data supplement). Scatter plots and AUC of the ROC of the PPD and HBHA-driven ELISPOT BALMC IFN-γ responses are shown Figure 2C and 2D, respectively.
Discussion
There are limited data about the profile of alveolar TB antigen-specific (ESAT-6, CFP-10, TB 7.7 and HBHA) immune responses [7, 8, 15, 16] , and the utility and feasibility of a lungorientated immunological approach for the rapid diagnosis of TB requires clarification. To our knowledge this is the first comparative diagnostic study of standardized antigen-specific (ESAT-6, CFP-10, TB 7.7, HBHA) and non-specific (PPD) pulmonary lymphocyte responses. We found that although the ELISPOT assay was inconclusive in almost a third of cases, when an evaluable result was generated, it had a high sensitivity and specificity. Moreover, TB was rapidly diagnosed more frequently by the ELISPOT assay than by smear microscopy.
Although the specificity of the RD-1 ELISPOT assay was high (94% at a cut-point of ≥ 20 SFC/ 10 6 BALMCs) the sensitivity in the definite TB group was 88%. The only published study examining pulmonary RD-1 responses using the T-SPOT.
® TB assay found a sensitivity of 100% using a cut-point of ≥ 30 spots per million BALMCs [16] . However, this preliminary study had a small sample size (n=8 definite and n=4 probable TB) and was performed in a low TB and HIV prevalence setting. Factors such as a larger sample size, HIV co-infection (though we found no difference when results were stratified by HIV status), host HLA phenotype, strain differences, immunosuppressive cytokines (e.g. IL-10 and TGF-β; [23] ), immunoregulatory T cells [24] , bronchoscopic technique, and our propensity to treat empirically for TB may have all contributed to the greater variability in sensitivity in our study. In keeping with our observations a recent study, using flow cytometry, showed that 19% of definite TB cases had no measurable ESAT-6 protein-specific lung immune responses [8] . There were 5 out of 48 non-TB patients (2 with lung carcinoma and 2 HIV positive) in whom the BAL ELISPOT IGRAs were positive. Although the relationship between lung cancer and TB is well described [25], and we cannot be certain that concomitant TB was not present, on follow-up we found no evidence of TB. Other possible explanations include transient or latent infection.
Test outcomes were poorer for the QFT-GIT assay despite using 1x10 6 cells per tube. The reasons for this are unclear. Varying the cut-point or the volume of medium in the QFT tube did not meaningfully improve results. We therefore presume that performance was poorer because the ELISA is inherently a less sensitive immunological technique. We cannot exclude the possibility that the QFT-GIT-specific antigen, TB 7.7, may be driving inhibitory pathways or immunosuppressive regulatory T cells [24] .
A major practical limitation of the BAL assays was the high proportion of inconclusive results (34 to 41%). The commonest cause was a non-functional positive control. There was no correlation with HIV status. Immunosuppressive cytokines [23, 26, 27] or cells, including immunosuppressive pulmonary macrophages and regulatory T cells [24] may explain these findings. We estimate that if SEB was used as a positive control throughout the study then the proportion of inconclusive RD-1 ELISPOT results would have dropped from 34 to 25%. Further studies are now required to determine whether user-friendly depletion of immunosuppressive cells can further improve the performance outcome. This would make the assay clinically more useful. The second commonest reason for inconclusive results was a high spot count in the negative control. Adjustment of the negative control ELISPOT cut-point did not significantly improve outcomes without compromising sensitivity. Notably, 22% of the cohort had evidence of colonization (positive bacterial or fungal culture in the absence of clinical disease) and high spot counts were significantly associated with HIV infection. Thus, although not proven, it is likely that that airway pathogen colonization, more common in high HIV and resource-poor settings, induces high spot counts in the T SPOT-TB assay by activating the BAL alveolar T cells. Other reasons for inconclusive results were significant discoloration (blue-out) of the ELISPOT wells and low numbers of cells harvested at bronchoscopy, particularly in technically difficult procedures.
Interestingly, there were many non-TB patients with presumed LTBI (blood RD-1 IGRA positive) who were BAL RD-1 IGRA negative. How do we explain these findings given that the lung is a major site of latent infection? In contrast to the peripheral blood compartment, which contains circulating lymphocytes, the alveolar compartment may not reflect what is happening in the interstitial tissue (site of infection) or mediastinal lymph nodes where the majority of T cells reside. Compared to the RD-1 ELISPOT assay the specificity of the PPD assay was relatively poor. A likely reason is the high exposure to environmental mycobacteria in a resource-poor setting. It is therefore, similar to the findings in a recent UK-based study (76% specificity) [8] , not useful as a rule-in test in clinical practice. By contrast, the sensitivity of PPD in our study was surprisingly and inexplicably low.
HBHA, whose antigenicity is dependent on methylation of the C-terminal domain and is upregulated in murine lungs infected with M. tb [20] , is a novel and relatively TB-specific virulence factor [18] . HBHA responses may be a sensitive marker of TB infection with the ability to distinguish latent from active TB [17, 28] . We therefore hypothesized that HBHA responses, which have not previously been evaluated using alveolar lavage cells, would be useful for the detection of pulmonary TB. However, HBHA, both in peripheral blood and BAL, had poor discriminatory value. The regulatory T cell profile, which may modulate HBHA responses [29] , is likely to be different in high burden countries and may explain these findings. The differential effect of M. smegmatis [19] [20] [21] vs. M.Bovis BCG-derived HBHA on IFN-γ responses, if any, is unclear.
We have taken several steps to limit study bias including initial experiments to determine optimum cell number and antigen concentration, blinding an experienced laboratory scientist to clinical details, performing BAL in a standardized manner, recruiting consecutive TB suspects over a fixed time period, and performing comparative analysis using several different antigens, assays and in both blood and BAL compartments. Nevertheless, the lack of association with HIV could be due to type 2 error. Larger studies are now required in different geographical settings to confirm these observations. Although the appropriateness of the ELISPOT assay in a resource-poor setting may be argued it could have utility in diagnostically challenging cases in a tertiary care setting in South Africa.
In summary, when an evaluable result is obtained the lung RD-1 ELISPOT response is a useful rapid immunodiagnostic test with a reasonably high sensitivity and specificity for pulmonary TB. However, clinical utility may be limited by the high number of inconclusive results. A lung-orientated approach to TB diagnosis is thus feasible but further work is necessary, using alternative test formats, biomarkers and/or antigens, to develop an improved assay prototype that will minimize inconclusive results. (ii) RD-1 ELISA-measured IFN-γ responses to ESAT-6/ CFP-10 and TB 7.7 antigens (QFT-TB-GIT assay; Cellestis, Victoria) were performed using 1x10 6 BALMCs re-suspended in 1ml of serum free medium in each tube. The cell number and volume used were derived through optimization experiments using BALMCs from 10 patients (see online data supplement). (iv) IFN-γ ELISPOT responses to HBHA (concentration of 100μg/ml derived from optimization experiments; see online supplement) were performed in duplicate using IFN-γ pre-coated ELISPOT plates. Methylated HBHA antigen was produced in cultures of Mycobacterium smegmatis 3.38 as previously described [19] [20] [21] .
All antigen-specific ELISPOT assays were enumerated using an ELISPOT reader and using 2x10 5 BALMCs per well. Results were deemed to be inconclusive if there were insufficient cells to perform the assay, if the positive control failed (indeterminate), there was a high spot count/ level in the negative control well/ tube, or, if there was high background discoloration of the ELISPOT wells precluding meaningful evaluation of the plate. Given the significant frequency of indeterminate results, in the second half of the study, in addition to phytohaemagglutinin (PHA), staphylococcal enterotoxin B (SEB) was used as a positive control.
Peripheral blood-derived antigen-specific IFN-γ responses
The following peripheral blood IFN-γ responses were evaluated in each patient according to the methods already described:
(i) RD-1 ELISPOT responses using 2.5x10 5 peripheral blood MCs/ well (T-SPOT. ® TB).
(ii) RD-1 ELISA using 1ml of whole blood per tube (QFT-GIT).
(iii) PPD ELISPOT responses using 2.5x10 5 peripheral blood MCs/ well.
(iv) HBHA ELISPOT responses using 2. BALMCs in the antigen-containing wells). In these three subjects serial spot counts are shown in Table   E1 . In summary, responses (cells/ well) were absent at 5 x 10 4 , were recordable at 1 x 10 5 and increased at 2 x 10 5 cells/well. Responses were not significantly better at 4 x 10 5 cells/well.
(ii) RD-1 ELISA assay (QFT-GIT): data obtained from 13 participants at different cell counts are summarized in Figure E1 . At the time of sample acquisition the disease status of the participants was unknown and three of the assays were inconclusive. Changing the volume of supernatant did not impact on the result ( figure 2E; n=4) . Thus, 1 x 10 6 cells per tube suspended in 1000ul of serum free medium was used ( Figure E2 ).
(iii) HBHA ELISPOT assay: the antigen concentration of M. smegmatis-derived HBHA is unknown.
Because of limited cell numbers HBHA optimization data were derived using PBMCs ( Figure E3 ).
Thus, 100 μg/ml of HBHA per well was used.
Statistical analysis:
Categorical variables were compared using the χ 2 test or Fisher exact test and continuous variables were compared using t-student test, whenever appropriate. Non-parametric tests (Mann-Whitney) were used for non-normally distributed variables. Concordance between tests was measured using the kappa co-efficient. Diagnostic accuracy, including 95% confidence intervals, was assessed using sensitivity, specificity, predictive values and area under the ROC in the TB and non-TB sub-groups; comparative analysis was also done by combining the definite and probable TB groups. The study satisfies the Standards for Reporting of Diagnostic Accuracy (STARD initiative) checklist (19) .
RESULTS
Causes of pulmonary infiltrates in the non-TB group
The most common causes of pulmonary infiltrates in the non-TB group were: 9 lung primary or metastatic carcinoma; 18 bacterial, pneumocystis or fungal pneumonia; 6 idiopathic interstitial pneumonias including non-specific interstitial pneumonitis, respiratory bronchiolitis interstitial lung disease, and usual interstitial pneumonitis; 3 sarcoidosis; 2 lymphocytic interstitial pneumonitis and several others with a variety of different pathologies.
Positive controls used in RD-1-driven ELISPOT assay
In 28 ELISPOT assays paired positive controls were used (PHA and SEB); of these significantly more PHA-driven than SEB-driven positive controls failed [1/28 (3%) vs. 7/28 (25%); p= 0. 02; Chi square; Table E2 ).
RD1-driven ELISA and ELISPOT assays
Performance outcome values for BAL and blood when the definite and probable TB groups were combined are shown in Table E3 .
BALMC/ PBMC IFN-
In an attempt to improve the discriminatory value of the ELISPOT assay we compared the BALMC/ PBMC IFN-γ ratio in the TB and non-TB groups. Whilst this ratio had a high diagnostic accuracy (AUC = 0.87 at a cut-point of > 0.092; 93% sensitivity and 71% specificity; Figure E4 ) it was no better that the BAL ELISPOT alone.
HIV effect on RD-1 responses T-SPOT. ® TB and QFT-GIT in the definite, definite + probable TB, and non-TB groups stratified by HIV status is shown in Figure E5 .
PPD-driven ELISPOT assays
Performance outcome values for BAL and blood when the definite and probable TB groups were combined are shown in Table E4 .
HBHA-driven ELISA and ELISPOT assays
Inconclusive results for RD1-driven ELISA and ELISPOT assays Inconclusive results occurred in many patients for several reasons (failure of positive or negative controls, inadequate cells etc.) Details of the reason for inconclusive results are contained in Table E8 . 0.68 * = manufacturer-recommended cut-point for peripheral blood of > 20 spot forming cells (SFCs) per million mononuclear cells either in the ESAT-6 or CFP-10 containing wells; ** = AUC-derived cutpoint with a high specificity at the expense of sensitivity. # = AUC-derived cut-point with the best possible specificity at a high sensitivity; Spec= specificity. n/a = not applicable (this is a dichotomized variable and hence the AUC cannot be calculated In all patients mycobacterial cultures were negative and follow-up did not reveal any evidence of clinical tuberculosis. None of the patients received anti-TB treatment.
*Actual values of the test results are given below the categorical result in rows 1 and 2. 
